Physician profile
Benjamin E Young
NPI 1326205113
$4,261.80
in general payments reported to CMS, 2019-2025
29 companies · $1,062 in 2025
The $1,062 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $152 · 2020: $140 · 2021: $179 · 2022: $700 · 2023: $1,039 · 2024: $990 · 2025: $1,062.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,046 · Education: $45.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,045.78 |
| Education | $45.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,126.64 | 2021-2025 | Linzess, Viberzi, Skyrizi |
| Pfizer INC. | $489.44 | 2022-2025 | |
| Janssen Biotech, INC. | $433.61 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $365.02 | 2019-2025 | Xifaxan |
| Celgene Corporation | $290.96 | 2022-2024 | Zeposia |
| Genzyme Corporation | $208.10 | 2022-2024 | |
| Lilly USA, LLC | $193.20 | 2024-2025 | Omvoh |
| Takeda Pharmaceuticals U.S.A., INC. | $192.42 | 2021-2025 | Entyvio |
| Ardelyx, INC. | $122.84 | 2022-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $98.94 | 2022-2025 | Dupixent |
| Celltrion USA INC. | $79.39 | 2024-2025 | Zymfentra, Vegzelma |
| Madrigal Pharmaceuticals | $78.88 | 2025 | Rezdiffra |
| Braintree Laboratories, INC. | $73.73 | 2020-2025 | Suflave, Sutab |
| Redhill Biopharma INC. | $67.01 | 2021-2023 | Talicia |
| Phathom Pharmaceuticals, INC. | $63.30 | 2024 | Voquezna |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $50.41 | 2025 | Iqirvo |
| Merck Sharp & Dohme LLC | $50.00 | 2022-2024 | Dificid |
| Boston Scientific Corporation | $40.84 | 2019 | |
| Ethicon US, LLC | $38.49 | 2021 | |
| Endogastric Solutions, INC | $28.01 | 2022 | |
| Allergan, INC. | $26.38 | 2019 | |
| Qol Medical, LLC | $25.94 | 2025 | Sucraid |
| Ultragenyx Pharmaceutical INC. | $20.60 | 2022 | |
| Daiichi Sankyo INC. | $19.70 | 2025 | Injectafer |
| Ironwood Pharmaceuticals, INC | $17.03 | 2023 | Linzess |
| Ferring Pharmaceuticals INC. | $16.83 | 2023 | Rebyota |
| Echosens North America, INC. | $15.10 | 2024 | Fibroscan |
| Evoke Pharma, INC. | $14.59 | 2024 | |
| Nestle Healthcare Nutrition INC. | $14.40 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.